Skip to content

Study · Observational study · n = 7 · 2018

3 results

Microvascular Density and Circulating Endothelial Progenitor Cells Before and After Treatment with Incretin Mimetics in Diabetic Patients.

De Ciuceis C, Agabiti-Rosei C, Rossini C, Caletti S, Coschignano MA, Ferrari-Toninelli G, Ragni G, Cappelli C, Cerudelli B, Airò P, Scarsi M, Tincani A, Porteri E, Rizzoni D

High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension10 Sept 2018Cited by 14 (Europe PMC)

PMID30203268 (opens in a new tab)DOI10.1007/s40292-018-0279-7 (opens in a new tab)PepBankPUB-30203268
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with type 2 diabetes, body mass index decreased during 4 weeks of liraglutide treatment.

    In plain wordsIn adults with type 2 diabetes, body mass index went down during liraglutide treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody mass index
    Study

    n = 7

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.6 mg per day for 1 week then 1.2 mg per day for 3 weeks · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    Patients treated with liraglutide (6 males 1 female, age 54 ± 12 years) showed a decrease in body mass index and blood pressure during treatment
    1 context sentence
    Summary · context
    Four diabetic patients were treated with exenatide (5 μg twice daily for 4 weeks and then 10 μg twice daily for 3 weeks) and 7 with liraglutide (0.6 mg per day for 1 week and then 1.2 mg per day for 3 weeks).
  2. 02HumanObservational studyEfficacy outcome

    In patients with type 2 diabetes, blood pressure decreased during 4 weeks of liraglutide treatment.

    In plain wordsIn adults with type 2 diabetes, blood pressure went down during liraglutide treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseBlood pressure
    Study

    n = 7

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    0.6 mg per day for 1 week then 1.2 mg per day for 3 weeks · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    Patients treated with liraglutide (6 males 1 female, age 54 ± 12 years) showed a decrease in body mass index and blood pressure during treatment
    1 context sentence
    Summary · context
    Four diabetic patients were treated with exenatide (5 μg twice daily for 4 weeks and then 10 μg twice daily for 3 weeks) and 7 with liraglutide (0.6 mg per day for 1 week and then 1.2 mg per day for 3 weeks).
  3. 03HumanObservational studyEfficacy outcome

    In patients with type 2 diabetes, circulating endothelial progenitor cells did not increase significantly after liraglutide, unlike after exenatide.

    In plain wordsIn adults with type 2 diabetes, liraglutide did not raise the number of circulating repair cells, while exenatide did.

    Peptide
    Liraglutide
    Outcome
    No significant changeCirculating endothelial progenitor cells (CD34+/KDR+)
    Study

    n = 7

    Outcome group
    Lung injury and fibrosis · Cardiovascular
    Studied dose
    0.6 mg per day for 1 week then 1.2 mg per day for 3 weeks · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    EPCs were significantly increased after treatment with exenatide, but not after treatment with liraglutide.
    2 context sentences
    Summary · context
    Treatment with exenatide, but not with liraglutide, was able to increase the number of circulating EPCs, possibly through an antioxidative/antiinflammatory effect.
    Summary · context
    Four diabetic patients were treated with exenatide (5 μg twice daily for 4 weeks and then 10 μg twice daily for 3 weeks) and 7 with liraglutide (0.6 mg per day for 1 week and then 1.2 mg per day for 3 weeks).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.